Biocom’s top priority is the safety of our members and the well-being of our employees. After careful consideration, Biocom has decided to transform our 2021 Global Life Science Partnering Conference to a fully virtual event. We know that many lives are being impacted and disrupted by COVID-19 and we are grateful to be able to continue offering our members valuable content in a safe manner.
Independent Drugs, Biologics, and Gene Therapy Regulatory Consultant
Curtis L. Scribner, MD, is an independent drug, biologic, and gene therapy consultant and based in Oakland, CA. He spent 10 years at the FDA/CBER reviewing CMC, nonclinical, clinical and regulatory development. He served for about 6 years at Intarcia as the Chief Regulatory Officer, and since that time as a consultant in early stage and strategic product development, especially for small and very small companies.